Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Glaukos's Business Segments
Glaukos's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Development and Commercialization of Ophthalmic Therapies
Total Revenue
$ 186
Countrys Reported
1
Revenue Share by Reportable Segment - Q2 FY2026
- Development and Commercialization of Ophthalmic Therapies100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Development and Commercialization of Ophthalmic Therapies | $ 186 | 100% |
Revenue Share by Country - Q2 FY2026
- US79.1%
Revenue by Geographic Country - Q2 FY2026
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 147 | 79.1% |
Revenue by Product & Service Category - Q2 FY2026
- Glaucoma63.9%
- Corneal Health15.2%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Glaucoma | $ 119 | 63.9% |
| Corneal Health | $ 28 | 15.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Glaukos
Glaukos Corporation is a medical technology company that focuses on developing and commercializing products and procedures to treat glaucoma, one of the leading causes of blindness worldwide. It was founded in 1998 and is headquartered in San Clemente, California, United States.
Glaukos Corporation offers a broad range of innovative glaucoma treatments that are designed to offer safe, long-lasting, and effective relief to patients suffering from this debilitating eye disease. The company's flagship product is the iStent, which is the world's first micro-bypass stent approved for use in patients with mild to moderate open-angle glaucoma. This tiny stent is placed into the eye during a minimally invasive procedure, through which it helps to alleviate intraocular pressure by improving the drainage of fluid from the eye.
Beyond the iStent, Glaukos offers a suite of glaucoma products that leverage the company's expertise in micro-scale devices and implantable technologies. These products include the iStent Inject, a next-generation version of the iStent that offers increased flow through two stents, as well as the iStent SA, which is designed for use in patients who are undergoing cataract surgery.
In addition to its product offerings, Glaukos has a robust research and development program that is focused on advancing the field of glaucoma treatment. This includes a pipeline of novel devices, surgical systems, and drug-delivery technologies that aim to address unmet needs in the glaucoma market.
The company's strong growth in recent years has been driven by its ability to provide compelling solutions to a significant unmet need in the ophthalmology marketplace. In 2020, Glaukos generated revenues of $196 million, a7% increase from the previous year.
Overall, Glaukos Corporation is a leading player in the ophthalmology space, with a strong track record of innovation and a commitment to improving patients' lives. As the company continues to invest in research and development, it is well-positioned to remain a key player in the glaucoma market for years to come.
Glaukos Corporation offers a broad range of innovative glaucoma treatments that are designed to offer safe, long-lasting, and effective relief to patients suffering from this debilitating eye disease. The company's flagship product is the iStent, which is the world's first micro-bypass stent approved for use in patients with mild to moderate open-angle glaucoma. This tiny stent is placed into the eye during a minimally invasive procedure, through which it helps to alleviate intraocular pressure by improving the drainage of fluid from the eye.
Beyond the iStent, Glaukos offers a suite of glaucoma products that leverage the company's expertise in micro-scale devices and implantable technologies. These products include the iStent Inject, a next-generation version of the iStent that offers increased flow through two stents, as well as the iStent SA, which is designed for use in patients who are undergoing cataract surgery.
In addition to its product offerings, Glaukos has a robust research and development program that is focused on advancing the field of glaucoma treatment. This includes a pipeline of novel devices, surgical systems, and drug-delivery technologies that aim to address unmet needs in the glaucoma market.
The company's strong growth in recent years has been driven by its ability to provide compelling solutions to a significant unmet need in the ophthalmology marketplace. In 2020, Glaukos generated revenues of $196 million, a7% increase from the previous year.
Overall, Glaukos Corporation is a leading player in the ophthalmology space, with a strong track record of innovation and a commitment to improving patients' lives. As the company continues to invest in research and development, it is well-positioned to remain a key player in the glaucoma market for years to come.
Glaukos Corporation is a prominent player in the medical technology field, focusing on the development and commercialization of advanced surgical devices and sustained pharmaceutical therapies specifically designed for treating glaucoma, corneal disorders, and retinal diseases. With a mission to enhance ophthalmic care, the company seeks to revolutionize treatment methodologies to improve patient outcomes, lower healthcare costs, and mitigate the complications related to conventional surgical techniques.
Segments
Glaukos operates primarily in two distinctive segments: Glaucoma and Corneal Health.
1. Glaucoma Segment
This segment is primarily dedicated to the research, development, and commercialization of groundbreaking medical devices aimed at the prevention and treatment of glaucoma, a leading cause of irreversible blindness.
- iStent: As Glaukos flagship product, the iStent represents a pivotal innovation in micro-invasive glaucoma surgery (MIGS). It is the first FDA-approved device of its kind meant for the primary treatment of mild-to-moderate open-angle glaucoma. The iStent reduces intraocular pressure (IOP) by enhancing aqueous humor drainage from the eye, thus improving visual function and quality of life for patients.
- iStent Inject: This second-generation device builds on the success of the original iStent by providing predictable and sustained IOP reduction. The iStent Inject creates a bypass between the anterior chamber of the eye and Schlemms canal, allowing for improved aqueous outflow.
- iStent SA: This product expands the range of treatment options in the MIGS category, designed to further enhance the outcomes of IOP management and deliver long-lasting relief for patients.
- iStent Supra: Targeting the suprachoroidal space, this device facilitates the outflow of aqueous humor from the anterior chamber directly into this space, which is a novel approach in glaucoma management.
- iDoseTR: Serving as a sustained-release drug delivery system, iDoseTR is designed to gradually release medication into the eye, providing long-lasting IOP control and improving adherence to treatment regimens.
Corneal Health Segment
The Corneal Health segment is centered on innovative approaches to treating various corneal diseases and disorders.
- iLink MicroShunt: This minimally invasive device is designed for the treatment of moderate-to-severe glaucoma, working synergistically with cataract surgery. It creates a new drainage pathway for aqueous humor, thereby lowering IOP efficiently.
- iDose Travoprost: This sustained-release system delivers Travoprost directly to the affected eye, minimizing the need for daily eye drops and providing reliable IOP reduction over sustained periods.
- iStent Infinite: A comprehensive solution for glaucoma management, the iStent Infinite allows for the implantation of multiple iStents in various locations within the eye, providing personalized treatment options for patients with more complex glaucoma.
Products
Glaukos portfolio includes a variety of innovative products aimed at improving the quality of care for patients with glaucoma and corneal diseases:
- iStent: An implantable device placed during cataract surgery that effectively lowers ocular pressure, decreasing reliance on glaucoma medications.
- iStent Inject: Designed for use during cataract procedures, this device provides long-lasting IOP reduction through a dual-implant mechanism.
- iStent Supra: This device offers unique access to the suprachoroidal space for more efficient fluid drainage.
- iDose: A pioneering implantable system that releases medication over time to maintain optimal intraocular pressure.
- iLink MicroShunt: This flexible, biocompatible tube channels aqueous humor from the anterior chamber to the subconjunctival space, minimizing trauma to the eye.
- iStent Infinite: A versatile glaucoma management system that allows for multiple iStent implants, tailoring treatment to individual patient needs.
Services
Glaukos extends its offering with a comprehensive range of services tailored for ophthalmic professionals and patients:
- Comprehensive Patient Evaluation Services: These services focus on the accurate diagnosis and treatment plans for both glaucoma and corneal disorders.
- Patient Education and Support Programs: Glaukos invests in initiatives that empower patients with knowledge about their conditions and treatment options.
- Ongoing Device Monitoring and Follow-Up Care: To ensure optimal performance and outcomes, Glaukos provides robust support for monitoring and maintaining devices implanted in patients.
- Continuing Education Programs for Ophthalmic Professionals: These programs are aimed at enhancing the skills and knowledge of medical professionals in the field of ophthalmology.
- Cloud-Based Data Platforms and Predictive Analytics: Utilizing modern technology, Glaukos offers platforms that assist healthcare providers in improving patient care through data-driven insights.
Conclusion
In summary, Glaukos Corporation stands out as a leader in ophthalmic innovation, providing a rich assortment of products and services designed to address the complexities of glaucoma and corneal disorders. With a focus on reducing healthcare costs, improving patient outcomes, and minimizing procedural complications, Glaukos continues to push the boundaries of what’s possible in ophthalmic care, thereby enhancing the lives of patients around the world.
Segments
Glaukos operates primarily in two distinctive segments: Glaucoma and Corneal Health.
1. Glaucoma Segment
This segment is primarily dedicated to the research, development, and commercialization of groundbreaking medical devices aimed at the prevention and treatment of glaucoma, a leading cause of irreversible blindness.
- iStent: As Glaukos flagship product, the iStent represents a pivotal innovation in micro-invasive glaucoma surgery (MIGS). It is the first FDA-approved device of its kind meant for the primary treatment of mild-to-moderate open-angle glaucoma. The iStent reduces intraocular pressure (IOP) by enhancing aqueous humor drainage from the eye, thus improving visual function and quality of life for patients.
- iStent Inject: This second-generation device builds on the success of the original iStent by providing predictable and sustained IOP reduction. The iStent Inject creates a bypass between the anterior chamber of the eye and Schlemms canal, allowing for improved aqueous outflow.
- iStent SA: This product expands the range of treatment options in the MIGS category, designed to further enhance the outcomes of IOP management and deliver long-lasting relief for patients.
- iStent Supra: Targeting the suprachoroidal space, this device facilitates the outflow of aqueous humor from the anterior chamber directly into this space, which is a novel approach in glaucoma management.
- iDoseTR: Serving as a sustained-release drug delivery system, iDoseTR is designed to gradually release medication into the eye, providing long-lasting IOP control and improving adherence to treatment regimens.
Corneal Health Segment
The Corneal Health segment is centered on innovative approaches to treating various corneal diseases and disorders.
- iLink MicroShunt: This minimally invasive device is designed for the treatment of moderate-to-severe glaucoma, working synergistically with cataract surgery. It creates a new drainage pathway for aqueous humor, thereby lowering IOP efficiently.
- iDose Travoprost: This sustained-release system delivers Travoprost directly to the affected eye, minimizing the need for daily eye drops and providing reliable IOP reduction over sustained periods.
- iStent Infinite: A comprehensive solution for glaucoma management, the iStent Infinite allows for the implantation of multiple iStents in various locations within the eye, providing personalized treatment options for patients with more complex glaucoma.
Products
Glaukos portfolio includes a variety of innovative products aimed at improving the quality of care for patients with glaucoma and corneal diseases:
- iStent: An implantable device placed during cataract surgery that effectively lowers ocular pressure, decreasing reliance on glaucoma medications.
- iStent Inject: Designed for use during cataract procedures, this device provides long-lasting IOP reduction through a dual-implant mechanism.
- iStent Supra: This device offers unique access to the suprachoroidal space for more efficient fluid drainage.
- iDose: A pioneering implantable system that releases medication over time to maintain optimal intraocular pressure.
- iLink MicroShunt: This flexible, biocompatible tube channels aqueous humor from the anterior chamber to the subconjunctival space, minimizing trauma to the eye.
- iStent Infinite: A versatile glaucoma management system that allows for multiple iStent implants, tailoring treatment to individual patient needs.
Services
Glaukos extends its offering with a comprehensive range of services tailored for ophthalmic professionals and patients:
- Comprehensive Patient Evaluation Services: These services focus on the accurate diagnosis and treatment plans for both glaucoma and corneal disorders.
- Patient Education and Support Programs: Glaukos invests in initiatives that empower patients with knowledge about their conditions and treatment options.
- Ongoing Device Monitoring and Follow-Up Care: To ensure optimal performance and outcomes, Glaukos provides robust support for monitoring and maintaining devices implanted in patients.
- Continuing Education Programs for Ophthalmic Professionals: These programs are aimed at enhancing the skills and knowledge of medical professionals in the field of ophthalmology.
- Cloud-Based Data Platforms and Predictive Analytics: Utilizing modern technology, Glaukos offers platforms that assist healthcare providers in improving patient care through data-driven insights.
Conclusion
In summary, Glaukos Corporation stands out as a leader in ophthalmic innovation, providing a rich assortment of products and services designed to address the complexities of glaucoma and corneal disorders. With a focus on reducing healthcare costs, improving patient outcomes, and minimizing procedural complications, Glaukos continues to push the boundaries of what’s possible in ophthalmic care, thereby enhancing the lives of patients around the world.